| 4ZYF: Discovery Of Nvp-Cgm097 - A Highly Potent And Selective Mdm2 Undergoing Phase 1 Clinical Trials In P53wt Tumors: Hdm2 (M Complexed With Nvp-Cgm097 reference: Discovery of a dihydroisoquinolinone derivative (NVP-CGM097) - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors., Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S, Berghausen J, Bouisset-Leonard M, Buschmann N, Pissot-Soldermann C, Rynn C, Ruetz S, Stutz S, Chene P, Jeay S, Gessier F, J Med Chem. 2015 Jul 16. PMID: 26181851 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).